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Polyclonal Antibody Production 
for Membrane Proteins via Genetic 
Immunization
Debra T. Hansen1,2,3,4, Mark D. Robida1,4,*, Felicia M. Craciunescu1,2,4,†, Andrey V. Loskutov1,†, 
Katerina Dörner3,4,‡, John-Charles Rodenberry1,#, Xiao Wang1, Tien L. Olson1,¶, Hetal Patel1,§, 
Petra Fromme2,3,4 & Kathryn F. Sykes1,4,||
Antibodies are essential for structural determinations and functional studies of membrane proteins, 
but antibody generation is limited by the availability of properly-folded and purified antigen. We 
describe the first application of genetic immunization to a structurally diverse set of membrane proteins 
to show that immunization of mice with DNA alone produced antibodies against 71% (n = 17) of the 
bacterial and viral targets. Antibody production correlated with prior reports of target immunogenicity 
in host organisms, underscoring the efficiency of this DNA-gold micronanoplex approach. To generate 
each antigen for antibody characterization, we also developed a simple in vitro membrane protein 
expression and capture method. Antibody specificity was demonstrated upon identifying, for the first 
time, membrane-directed heterologous expression of the native sequences of the FopA and FTT1525 
virulence determinants from the select agent Francisella tularensis SCHU S4. These approaches will 
accelerate future structural and functional investigations of therapeutically-relevant membrane 
proteins.
Membrane proteins are the molecular interface between host and pathogen, yet these key proteins provide unique 
challenges for structural elucidation1 and for their use in developing not only therapeutics2 but also diagnos-
tics and vaccines. Target-specific monoclonal antibodies have allowed the determination of novel membrane 
protein structures during electron cryomicroscopy by increasing the size of the target3, and during crystallog-
raphy4 by stabilizing unique protein conformations5–8, providing crystal lattice contacts9–11, and allowing struc-
ture solution via molecular replacement10–12. Monoclonal antibodies that recognize specific conformations of 
membrane-embedded signal pathway proteins allow the exciting development of novel therapeutics13. Towards 
antibody production for membrane proteins, there is often a limitation in the availability of highly-purified or 
natively-folded target antigen. Therefore, we explored the genetic immunization approach14 in order to generate 
antibodies that target membrane proteins.
Surprisingly, the efficiency of genetic immunization as applied to membrane proteins is unknown, since appli-
cation of this method has been described only or for collections of soluble proteins15 or for individual membrane 
protein targets16–18. For these individual membrane proteins, the reported operational serum dilutions of ≤ 1:200 
for the human thyrotropin and neurokinin-1 GPCRs16,17 and for human nephrin18 suggest room for improve-
ment. The biolistic approach, using only genes as the source of antigen, has generated monoclonal antibodies that 
recognize native epitopes of membrane proteins17,18, including modifications such as glycosylation18. Additional 
groups have used genetic immunization alone to generate antibodies with therapeutic potential, albeit using 
proprietary methods19,20.
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Here we describe an efficient approach that yielded antibodies against the majority of 17 membrane proteins 
from Biosafety Level 3 pathogens. The SCHU S4 isolate of Francisella tularensis is one of the most pathogenic 
bacteria known due to its capacity for fatal infection from as few as ten cells21. F. tularensis causes the disease 
tularemia and is a model intracellular bacterial pathogen given its capacity to evade the immune response and 
to infect numerous cell types22. The arthropod-borne African swine fever virus (ASFV) causes an untreatable, 
highly-lethal hemorrhagic porcine disease that is an economic threat in Africa and eastern Europe23. The endemic 
existence of both these pathogens throughout numerous environmental sources makes eradication implausi-
ble24,25. Investigations with endogenous protein from these organisms are constrained by biosafety require-
ments and select agent status. To support studies of membrane proteins that are important in pathogenesis, we 
developed DNA-based approaches to generate and characterize antibodies against a set of membrane proteins 
(Supplementary Table 1) that were targeted for structural studies as part of the U.S. National Institutes of Health’s 
Protein Structure Initiative (PSI:Biology). Many of these targets are expected to provide novel membrane protein 
structures as they lack obvious sequence homologs outside of the Francisella genus and the Asfarviridae virus 
family.
Results and Discussion
In vitro expression and purification of membrane proteins by IVT-HMB. To facilitate analyses of 
the sera, we developed a novel in vitro approach for simultaneous expression and capture of each of the mem-
brane protein targets. We optimized a commercially available in vitro protein translation system and included 
unmodified tosylactivated magnetic beads in the reaction to yield the method IVT-HMB (in vitro translation in 
the presence of hydrophobic magnetic beads; Fig. 1a). Tosylated beads are typically used to capture protein via 
covalent modification of the bead surface through replacement of the tosyl leaving group with a capturing ligand. 
Rather, we found that unmodified beads allowed non-covalent capture of each of the 17 membrane protein tar-
gets at high purity (Fig. 1b,c). Using IVT-HMB, we obtained 15 of the 17 targets in full-length form (Fig. 1b). 
The remaining two targets were captured in multiple truncated forms that in total represented most of the length 
of each target sequence (Fig. 1c). The capture process may be based on bead surface adherence to hydrophobic 
residues that are normally buried in the membrane or that lie internal to the protein’s tertiary structure, but are 
exposed during the in vitro synthesis events.
Towards characterization of polyclonal sera, the IVT-HMB approach effectively simplified antigen prepa-
ration by precluding the need to use endogenous protein or to purify detergent-solubilized or urea-denatured 
membrane protein, since the protein can be directly used without a separate elution step. Although the IVT-HMB 
protein is not expected to be natively-folded, as GFP fluorescence of the bead-bound protein was not detectable 
above empty vector controls, this protein is suitable for evaluation of polyclonal immune responses since a sig-
nificant proportion of polyclonal antibody species recognizes linear epitopes26. The resulting yields of 5–20 μ g of 
membrane protein per 500 μ L of IVT-HMB reaction were sufficient to allow completion of ELISA and Western 
analyses of the sera from 5 mice. Other unique advantages of the method include eliminating any need for tagging 
the target protein or including a capturing ligand on the beads. Limitations of the current IVT-HMB method may 
be in identifying conformationally-specific monoclonal antibodies and antibodies for antigens that are highly 
modified post-translationally. However, we expect that IVT-HMB can be adapted to in vitro systems that provide 
such modifications27.
Antibody production by genetic immunization using DNA-gold micronanoplexes. Biolistic 
immunization with the gene gun uses a burst of gas to propel DNA-bound gold particles to the dermal tissues 
Figure 1. In vitro generation of purified membrane protein antigen. (a) Schematic of the IVT-HMB method 
for expression and purification of membrane proteins. (b) Generation of full-length proteins for 15 targets in 
the form of fusions to green fluorescent protein (GFP). (c) Generation of partial-length proteins for F. tularensis 
FTT0759 (305 amino acids) and ASFV CD2v (360 amino acids) in the form of fusions to thioredoxin. Shown 
are SDS-PAGE visualized by Coomassie stain (left panel of b) or silver stain (remaining panels in b,c) and 
containing, per lane, magnetic-bead purified fractions from 10 μ L of IVT-HMB. Molecular weight (MW) in 
kDa is indicated, and arrowheads indicate the predicted migration position. BSA, bovine serum albumin.
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(Fig. 2a). This method of genetic immunization leads to direct transfection of dendritic cells28 and in vivo expres-
sion of the encoded protein in both the dermal tissues and the lymph nodes28,29. Although biolistic immuniza-
tion is more technically challenging than immunization by DNA needle injection, biolistic delivery effects a Th2 
response, which is specifically associated with antibody production, in comparison to the Th1 response favored 
upon DNA injection30.
The DNA-gold particles used in this study were micronanoplexes (Fig. 2a)31. Micronanoplexes are complexes 
of two differently-sized gold particles: micron-sized (1–2 μ m) gold particles that are coated with polyethylen-
imine (microgold-PEI; Fig. 2a)32, and nanometer-sized gold particles that are generated upon modification with 
cysteamine and DNA (DNA-nanogold; Fig. 2a)31,33. The micron-sized particles allow dermal penetration, and 
the nanometer-sized particles provide a high surface area for DNA binding. Micronanoplexes allow an order of 
magnitude higher DNA-binding capacity compared to micron-sized particles alone31. Micronanoplexes have pre-
viously been used to express luciferase in mice31 and to identify vaccine antigen candidates that provided protec-
tion against the bioterrorism agent Burkholderia mallei34. The results presented here represent the first described 
application of DNA-gold micronanoplexes to antibody production.
To generate polyclonal antibodies, each antigen-encoding gene was cloned as a full-length open reading frame 
with its natural codon usage into the novel vector pCMVi-LSrCOMPTT (Fig. 2b), and several targets were also 
cloned into the vaccine construct pCMVi-UB (Fig. 2c)35. pCMVi-LSrCOMPTT is based on vectors that were 
used to produce antibodies against proteins lacking transmembrane domains15. pCMVi-LSrCOMPTT allows 
expression of the target membrane protein as a fusion with a 174-residue sequence containing the following four 
immune-stimulating domains (Fig. 2b). “LS” is the 24 amino acid secretion leader sequence from the human 
α 1-antitrypsin gene36, which allows targeting of the fused protein to the plasma membrane37. To our knowledge, 
this work is the first reported use of the LS sequence for generation of antibodies against membrane proteins. “r” 
is a randomly-generated 23 amino acid peptide that was previously shown to be immunogenic15. “COMP” is the 
45 amino acid cartilage oligomeric matrix protein assembly domain from the pentameric rat matrix protein38. 
“TT” is a 50 amino acid sequence containing tetanus toxoid epitopes, which has been used to overcome humoral 
tolerance39. All plasmids used in this study and their sequences are available from the PSI:Biology-Materials 
Repository at DNASU40 (Supplementary Table 2).
A typical immunization schedule was applied and consisted of a double prime plus 2–4 genetic boosts until 
target-specific ELISA titers of 1:1000 were achieved, in comparison to naïve mice (Supplementary Fig. 1a–q). 
Antibody specificity was confirmed in Western blots (Fig. 2d and Supplementary Fig. 1a–q). Biolistic immuniza-
tion using pCMVi-LSrCOMPTT yielded antibodies for 12 membrane proteins, including 11 of 14 targets from F. 
tularensis and one of three targets from ASFV (Fig. 2d). Using altered adjuvants, improved titers were obtained 
Figure 2. Production of high-specificity polyclonal antibodies for membrane proteins from F. tularensis 
and ASFV. (a) Overview of DNA-gold micronanoplex bullet production. (b,c) Genetic immunization vectors 
pCMVi-LSrCOMPTT (b) and pCMVi-UB35 (c). (d) Representative Westerns on IVT-HMB target protein using 
immunizations with pCMVi-LSrCOMPTT, except for (*) which used pCMVi-UB. Positive immunoblots were 
for 5 out of 5 mice and using a serum dilution of 1:2000 unless noted. Individual Western and ELISA results are 
in Supplementary Fig. 1a–q.
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with fewer boosts (Supplementary Fig. 2a–k), which suggests the possibility of further enhancement upon sys-
tematic investigations.
For nine targets that yielded negative immunoblots at a serum dilution of ≤ 1:500, the corresponding genes 
were cloned into pCMVi-UB (Fig. 2c)35, which allows expression of the target as a fusion with mouse ubiqui-
tin. pCMVi-UB has been used previously to evaluate protective antigens in vaccine studies (reviewed in41) but 
has also yielded strong antibody responses35,42. The ubiquitin sequence contains the Gly76Ala mutation to pre-
vent de-ubiquitination43. The expressed protein is not deliberately membrane-directed and may be expected to 
undergo MHC I presentation. We found that pCMVi-UB yielded a high response for the p54 envelope protein 
from ASFV (Fig. 2d and Supplementary Fig. 3a,b). ELISA responses for the other eight targets were not appreci-
ably higher than in the presence of negative control IVT-HMB products (Supplementary Fig. 3a, dashed lines). 
The lack of measurable response for these eight targets is not an unbiased predictor of antibody generation by 
pCMVi-UB, since the antigens tested also yielded moderate or no reactivity in pCMVi-LSrCOMPTT.
Boosts with protein from IVT-HMB. We further noted that boosting with antigen from IVT-HMB reac-
tions yielded higher ELISA titers (Supplementary Fig. 2f,j,k). However, this reactivity may be due in part to irrel-
evant proteins (Supplementary Fig. 3c), possibly those visible as background bands in gels containing captured 
antigen (Fig. 1b,c). It is also not apparent whether the captured antigen contains folded domains. Nevertheless, for 
the eight pCMVi-UB constructs that lacked a DNA response (Supplementary Fig. 3a), target-specific reactivity 
was not observed in immunoblots following two boosts with IVT-HMB protein.
Method appraisal. Importantly, success with this genetic immunization approach generally correlated with 
previous reports of target-specific immunogenicity in infected and immunized hosts (Supplementary Table 1, col-
umn “Reported immunogenicity”). The exceptions were CD2v, for which host recognition has been described for 
only a highly glycosylated form44, and F. tularensis FupB, for which antibodies were raised in rats from a recombi-
nant fragment45. The efficiency of our method (71%) also approaches that described for non-transmembrane pro-
teins, which was 84% (n = 100) using biolistic immunization with micron-sized gold and codon optimization15, 
and 78% (n = 18 proteins) or 83% (n = 6), respectively, using tail or limb vein injection of DNA46.
Our approach is expected to have wide applicability, given that robust antibodies were generated for more 
than half of the targets from two disparate hosts and across a structurally diverse set of membrane proteins. The 
targets included ten α -helical, seven β -barrel, and two lipidated proteins (Supplementary Table 1). Of interest will 
be whether this method can be adapted to better recognize targets that are poorly immunogenic by any approach, 
such as for ion channels that consist mainly of membrane-buried α -helices47 and for highly conserved targets 
whose autoreactive B cells would likely be removed by tolerance checkpoints48. Indeed, our approach yielded no 
measurable serum reactivity for the two most hydrophobic targets, FTT0759 and the CapC subunit of the cap-
sule biosynthesis complex. This result is consistent with the well-known poor immunogenicity of hydrophobic 
regions, and is usually attributed to the low structural complexity of these stretches. It will be of interest to deter-
mine whether improved recognition can be achieved by the use of codon-optimized genes or by co-immunization 
of subunits that normally exist as part of a membrane protein complex (F. tularensis CapBCA49). Further method 
development may be guided by improved understanding of the membrane protein expression pathways under-
taken by these targets upon immunization as well as the mechanisms of immune recognition upon biolistic 
immunization, which have generally focused on cellular, not humoral, immune responses and have not been 
specifically explored for integral membrane proteins.
Antibody-based characterization of membrane-targeting upon recombinant expression. To 
support structural studies of membrane proteins involved in pathogenesis, we used the antibodies to charac-
terize membrane-targeting of several proteins from F. tularensis upon recombinant expression in Escherichia 
coli. Because several targets could not be purified when expressed as fusions with purification tags, we analyzed 
expression of targets that lacked purification tags. This tag-free approach evaluated whether membrane-targeting 
alone could be achieved in E. coli using the native F. tularensis protein sequences and independently of other F. 
tularensis-specific factors.
Western analyses using antibodies against four tag-less targets confirmed their expression in vitro (Fig. 3a, 
lane “IVT-HMB, target”). In contrast, in vivo expression in E. coli was undetectable for the outer membrane efflux 
protein (OMEP; Fig. 3a, lane “Total protein, target”). PilQ was poorly expressed in vivo (Fig. 3a, lane “Total pro-
tein, target”), and little of this membrane protein appeared to be membrane-directed as indicated by detergent 
solubility (Fig. 3a, lane “DDM, target”; DDM = n-dodecyl β -D-maltoside). These results suggest that OMEP and 
PilQ may require alternative strategies to generate these proteins for structural analyses. In comparison, in vivo 
expression was more apparent for the virulence determinants FopA and FTT1525 (Fig. 3a, lanes “Total pro-
tein, target”). Importantly, the antibody reagents generated in this study allowed membrane-targeting of FopA 
and FTT1525 to be demonstrated for the first time, by detection of these proteins in DDM-solubilized fractions 
(Fig. 3a, lanes “DDM, target”). These immunoblots additionally demonstrate the target specificity of some of the 
non-enriched sera obtained in this study, as evidenced by the lack of additional bands that represent proteins 
from host cells (Fig. 3a, lane “BL21(DE3)”) or proteins from IVT-HMB reactions (Fig. 3a, lane “IVT-HMB, no 
DNA”). Use of the remaining sera in future studies will require the application of appropriate controls50 to avoid 
misinterpretation of data.
Similar analyses with purification fractions of a recombinant form of the BamA major subunit of the F. tula-
rensis β -barrel assembly machine indicated virtually no membrane-targeting in E. coli (Fig. 3b, lanes “LDAO” 
and “DDM”; LDAO = N,N-dimethyldodecylamine N-oxide). Evidence of strong expression (Fig. 3b, lane “mem-
brane”) suggests that recombinant BamA may be a candidate for refolding from inclusion bodies, towards struc-
tural investigations.
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Figure 3. Western analyses of tag-free F. tularensis membrane proteins identifies membrane-targeting 
upon recombinant expression. (a) Immunoblots probed with 1:2000 dilution of serum. IVT-HMB samples 
contain 100–200 ng of target protein, or beads from an equivalent reaction volume lacking template DNA. 
Total protein and detergent-solubilized samples contain protein from 16 μ L of culture in which the target 
protein or an unrelated target was expressed. DDM, n-dodecyl β -D-maltoside. The unrelated targets used in 
the blots were, from top to bottom: PilQ, OMEP, FTT1525, and TolC. (b) Western analyses of the membrane 
fraction, cytosolic fraction, and detergent-solubilized proteins of the membrane fraction upon expression of F. 
tularensis BamA containing the signal sequence (ss) from E. coli BamA. The BamA protein is identified (yellow 
triangles). Lanes contain protein from the equivalent of 100 μ L of culture. Serum dilution was 1:500. LDAO, 
N,N-dimethyldodecylamine N-oxide.
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Conclusions
In summary, we used an immunization approach that precludes the need for purified protein14 to generate poly-
clonal antibodies against membrane proteins. To facilitate characterization of the antibodies, we developed a sim-
ple, modified in vitro reaction to simultaneously express and capture membrane protein antigen. Finally, Western 
analyses using these antibodies demonstrated antibody specificity and also identified promising candidate target 
membrane proteins for future structural studies. As studies with these membrane proteins progress, monoclonal 
antibodies will be generated from B cells isolated from genetically immunized hosts (Supplementary Methods). 
The techniques and materials described here will support the elucidation of the mechanisms of pathogenesis and 
the development of infectious disease therapies.
Methods
Membrane protein targets. Membrane proteins in this study (Supplementary Table 1) were selected by 
the Center for Membrane Proteins in Infectious Diseases (MPID; grant GM094599), as part of the PSI:Biology 
program under the U.S. National Institutes of Health’s Protein Structure Initiative. Information on MPID targets 
is available at the Structural Biology Knowledgebase Technology Portal51 (http://sbkb.org). Due to technical diffi-
culties that are commonly encountered when working with membrane proteins, the methods are presented here 
in necessary detail.
General cloning information. Genes encoding the membrane proteins were amplified from genomic DNA 
using iProof High-Fidelity DNA Polymerase (Bio-Rad #172-5302). Francisella tularensis subsp. tularensis SCHU 
S421 genomic DNA was provided by Drs. C. Rick Lyons, Terry H. Wu, and Jason Zsemlye (University of New 
Mexico). ASFV genomic DNA from the highly virulent isolates Georgia 2007/152 and Malawi Lil 20/153 was 
provided by Dr. Linda K. Dixon (The Pirbright Institute, United Kingdom). Unless noted, cloning was achieved 
using the In-Fusion HD Cloning Plus system (Clontech #638910). This ligation-independent system allows sim-
ple matching between 15 base pairs of each end of a PCR-derived insert with the ends of the linearized parent 
vector. Plasmid DNA was prepared with the QIAprep Spin Miniprep or Plasmid Maxi system (QIAGEN #27106 
and #12163, respectively). DNA elutions were done using molecular grade water. Sequence confirmation of the 
complete insert in each plasmid clone was performed at the School of Life Sciences DNA Laboratory at Arizona 
State University. Vectors used in this study and representative primers are in Supplementary Tables 2 and 3, 
respectively.
Vectors for in vitro protein expression. Protein used to characterize most of the sera was generated in 
IVT-HMB reactions from pRSET-natGFP constructs (Fig. 1b), which yields target protein fused to the C-terminal 
folding reporter GFP sequence54. Ligation-independent cloning into pRSET-natGFP and pRSET-natGFPHis was 
accomplished using BseRI-digested vector. Because cleavage occurs outside of the BseRI recognition site, and 
owing to vector design55, digestion with BseRI in these vectors circumvents inclusion of any BseRI recognition 
site sequence in the resulting subclones.
Membrane proteins that were used in protein boosts and for some sera analyses were prepared from pET-
32b-TEV constructs (Supplementary Fig. 4). pET-32b-TEV allows expression of the target membrane protein as a 
fusion with an N-terminal sequence consisting of E. coli thioredoxin, hexahistidine, thrombin cleavage site, S-tag, 
and TEV protease cleavage site (Supplementary Fig. 4). Target sequences with stop codons were cloned in-frame 
into pET-32b-TEV using the BamHI and HindIII restriction sites, except that ASFV p54 used BamHI and SalI.
Linear expression element (LEE) constructs for in vitro protein expression. Full-length forms of 
FTT0759 and CD2v could not be obtained from IVT-HMB reactions as GFP-fusions using pRSET-natGFP or as 
thioredoxin-fusions using pET-32b-TEV. Therefore, these two targets were expressed as multiple target fragments 
from PCR-generated linear expression elements (LEEs)56 (Fig. 1c). The constructed LEEs generated each target 
fragment as a fusion with N-terminal thioredoxin and C-terminal histidine-tag sequences (Supplementary Fig. 
5a–f). Schematics of the LEEs for FTT0759 and CD2v and are shown in Supplementary Fig. 5a,d, respectively. 
The expressed ORF is flanked by a transcription promoter, translational signals, and a transcription terminator 
(Supplementary Fig. 5a,d). Detailed DNA and protein sequences of representative LEEs for FTT0759 and CD2v 
are in Supplementary Fig. 5b,c,e,f. Oligonucleotides used for generation of LEEs are detailed in Supplementary 
Table 4.
FTT0759 fragments were selected to avoid interruption of predicted transmembrane helices. Alpha-helical 
transmembrane segments were predicted using TMHMM57, SOSUI58, TopPred59, and TMPred60. The following 
fragments for FTT0759 were obtained by IVT-HMB: amino acid residues 1–158, 149–250, 59–128, 59–192, and 
120–220 (Fig. 1c). IVT-HMB products were not obtained for the following fragments: 59–220, 59–305, 149–305 
and 179–305. Therefore, no products were obtained for all three fragments encompassing residues 251–305.
LEE template DNA for use in IVT-HMB reactions was generated in three steps. (1) Each of the three LEE 
DNA segments shown at the bottom of Supplementary Fig. 5a,d was generated in a 30 μ L reaction using Bio-Rad 
iProof High-Fidelity DNA Polymerase, 250 μ M of each dNTP (Life Technologies #10297-018), 5–10 ng of tem-
plate DNA, and 200 μ M of each primer. Reaction conditions were 98 °C × 30 s; 27–30 cycles of (98 °C × 10 s; 
55 °C × 30 s; 72 °C × 15 s/kb); and 72 °C × 1 min. Products were gel-purified with a QIAquick Gel Extraction Kit 
(Qiagen #28706) and quantified by absorbance at 260 nm. (2) LEE segments were assembled into a full-length 
product in a 30 μ L reaction using iProof High-Fidelity DNA Polymerase, 250 μ M of each dNTP, and 0.16 pmol 
of each LEE segment from step (1). Reaction conditions were 98 °C × 30 s; 10 cycles of (98 °C × 10 s; 55 °C × 30 s; 
72 °C × 1 min/kb); and 72 °C × 10 min. (3) Full-length LEEs were amplified in a 50 μ L reaction using PrimeSTAR 
Max DNA Polymerase (Clontech #R045), 2 μ L of the assembly reaction from step (2), and 10 μ M of each primer 
T7Pro-FOR and T7Ter-REV. Reaction conditions were 30 cycles of (98 °C × 10 s; 55 °C × 15 s; 72 °C × 10 s/kb). A 
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2 μ L sample was analyzed on an agarose gel. DNA from the remaining reaction was purified using the Agencourt 
AMPure XP PCR magnetic particle purification system (Beckman Coulter #A63880), eluting with 40 μ L of water. 
This AMPure purification step was critical for obtaining high protein yields in IVT-HMB reactions. DNA prod-
ucts were quantified by absorbance at 260 nm.
The 3′ LEE fragments in Supplementary Fig. 5a,d were originally constructed from multiple PCR reac-
tions. For future use as template DNA, one of each LEE for FTT0759 and CD2v was subcloned into the 
pJET1.2 vector using CloneJET PCR Cloning (Clontech #K1231) and sequence-verified, yielding subclones 
pJET1.2-LEE-Trx-FTT0759aa59–128 and pJET1.2-LEE-Trx-EP402Raa10–202.
Vectors for genetic immunization. pCMVi vector constructs are designed to express target proteins 
upon genetic immunization of mice15. The pCMVi vectors described in this study contain the cytomegalovirus 
(CMV) immediate-early promoter enhanced by a chimeric intron (human β -globin and an immunoglobulin 
gene) upstream of the target gene, and the human growth hormone terminator downstream of the target gene.
The novel vector pCMVi-LSrCOMPTT (Fig. 2b) contains the backbone of pCMVi1015 plus three alterations: 
(i) the tetanus toxoid epitopes from pBQAP-TT15 were added between the COMP domain and the target ORF, 
(ii) the transcription terminator from the human growth hormone gene replaced that from the rabbit β -globin 
gene14, and (iii) a strong Kozak sequence61 was included near the “LS” secretion leader sequence. Target ORFs 
with stop codons were cloned in-frame into pCMVi-LSrCOMPTT using the BglII and HindIII sites, except ASFV 
p54 used BglII and XbaI. CD2v was also cloned into the pCMVi-LS vector35.
Nine target ORFs were cloned into pCMVi-UB35 in-frame with and 3′ of the mouse ubiquitin sequence using 
the BglII and BamHI restriction sites. The CD2v ORF in pCMVi-UB was derived from protein expression con-
structs and therefore had been optimized in the first nine codons for expression in E. coli.
Adjuvant vectors for genetic immunization. pCMVi-LS-LTA-R192G and pCMVi-LS-LTB encode 
the enterotoxigenic E. coli heat-labile enterotoxin subunits A (mutant) and B, respectively34. An amendment 
of the cloning method is described here. For both plasmids, the large EcoRI/XbaI fragment of pCMVi-UB35 
provided the backbone, into which the following sequence was generated using overlapping oligonucleotides: a 
Kozak sequence, the N-terminal 24 amino acid leader sequence (LS) from the human α 1-antitrypsin gene, and a 
mouse-codon-optimized sequence encoding the enterotoxigenic E. coli heat-labile enterotoxin subunit A (LTA; 
amino acids 30–269 of NCBI accession no. ABV16233.1, with mutations R192G and N189D) or subunit B (LTB; 
amino acids 2–104 of NCBI accession no. ACJ23372.1). The R192G mutation eliminates toxicity by abolishing 
proteolytic processing of the A subunit, while still conferring adjuvant activity62.
CpG oligodeoxynucleotide adjuvants. To stimulate antibody production, unmethylated CpG oligodeox-
ynucleotides (ODNs) that mimic the presence of foreign DNA (reviewed in63) were included as adjuvants. Class 
B CpG ODN 2006 (5′ -TCGTCGTTTTGTCGTTTTGTCGTT-3′ ) with complete phosphorothioate linkages was 
purchased from Sigma. Class C CpG ODN 2395 (5′-TCGTCGTTTTCGGCGCGCGCCG-3′ ) with complete 
phosphorothioate linkages was purchased from Life Technologies. CpG ODNs were suspended in water.
Vectors for in vivo expression in E. coli. Tag-free expression constructs for FopA, PilQ, OMEP, and 
FTT1525 (Fig. 3a) were generated by cloning the ORFs with a strong double stop codon signal (TAATAA) into 
BseRI-digested pRSET-natGFPHis55.
pCDF-BAD was generated by D.T.H. in the laboratory of Jeffrey L. Hansen (Medical University of 
South Carolina) by ligase cloning into the PacI and XbaI sites of pCDFDuet-1 (Novagen), which confers 
spectinomycin-resistance and contains the CloDF13 origin of replication. The cloned insert contained the 
arabinose-inducible promoter and the E. coli rrnB T1T2 transcription terminator sequences from pBAD1864 sep-
arated by a novel polylinker/RBS sequence consisting of NotI-PmeI-AGAAGGAGATTA-NdeI-XhoI-AscI-AatII. 
The subclone pCDF-BAD-EcBamA-FTT1573 was generated using the NdeI and XhoI sites of pCDF-BAD. The 
expressed protein contains a homologous E. coli BamA signal sequence (amino acids 1–21 from NCBI accession 
no. P0A940) fused to the full-length F. tularensis BamA (amino acids 24–792) following signal sequence cleavage 
as predicted by SignalP 4.065.
Production of membrane proteins serving as antigens by IVT-HMB. The IVT-HMB (in vitro trans-
lation in the presence of hydrophobic magnetic beads) reaction was based on the Expressway Maxi Cell-Free 
E. coli Expression System (Life Technologies #K9900-97). Each 100 μ L of the system’s Total Reaction solution 
consisted of 50 μ L of Starter Reaction solution and 50 μ L of Feed Reaction solution. Reactions were performed in 
1.5 mL Protein LoBind tubes (Eppendorf #022431081) or in 96-well plates (1.2 mL per square well, U-bottomed, 
with sealing lids; ABgene #AB-1127). Due to the need to maintain suspension of the beads, yields were reproduc-
ible when using 50–400 μ L of Total Reaction volume per tube or well. For each 100 μ L of Total Reaction solution, 
25 μ L of Dynabeads M-280 Tosylactivated (Life Technologies #142.04) were washed three times in phosphate 
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) by pelleting on 
a magnet (Life Technologies #123-20D). The 50 μ L Starter Reaction solution was prepared on ice by combining 
the following Expressway System components: 20 μ L of E. coli slyD− extract; 20 μ L of 2.5X IVPS Rxn Buffer; 
1.25 μ L of 50 mM amino acids solution (19 amino acids, without methionine); and 1 μ L of 75 mM methionine. 
Subsequently added was 1 μ L of a solution prepared at room temperature and consisting of one tablet of Complete 
Mini, EDTA-free Protease Inhibitor (Roche #11836170001) dissolved in 200 μ L of room-temperature water; 
1.25 μ L of RNase Inhibitor at 40 units/μ L (New England BioLabs #M0314L); and 1 μ L of T7 Enzyme Mix from 
the Expressway System. The resulting 45.5 μ L mixture was used to suspend the washed and pelleted beads. This 
bead mixture was added to a 4.5 μ L solution containing the DNA template at the optimal concentration of 1 μ g of 
plasmid DNA or 0.5 μ g of AMPure-purified LEE DNA. When necessary, template DNA had been concentrated 
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by speed vacuum centrifugation and then suspended in water. IVT-HMB reactions were incubated at 30 °C 
with shaking at 530–550 rpm, such as in a Thermomixer R (Eppendorf #022670107) or a HiGro Microplate Cell 
Incubator for 96-Well Plates (Digilab #JHGA0296OH). After 30 min, 50 μ L of Feed Reaction solution was added, 
which consisted of 20.5 μ L of water, 25 μ L of Expressway 2X IVPS Feed Buffer, 1.25 μ L of 50 mM amino acids 
solution (without methionine), 1 μ L of 75 mM methionine, 1 μ L of Protease Inhibitor solution, and 1.25 μ L of 
RNase Inhibitor. Incubation was continued at 30 °C with shaking for 3.5 h. Beads were washed three times in PBS 
(200 μ L per 100 μ L of Total Reaction solution) before suspension in PBS and storage at − 20 °C.
SDS-PAGE analyses of IVT-HMB products were done by suspension of magnet-pelleted beads in 1X 
SDS-PAGE Loading Solution, which was 1X XT Sample Buffer (Bio-Rad #161–0791) containing 715 mM of 
2-mercaptoethanol. Prior to loading, these samples were heated at 90 °C for 5 min. Gels were 4–12% Bis-Tris 
polyacrylamide (Life Technologies #NP0329BOX) that were run in 50 mM 3-(N-morpholino)propanesulfonic 
acid, 50 mM tris(hydroxymethyl)aminomethane, pH 7.7, 0.1% sodium dodecyl sulfate (SDS), and 1 mM ethyl-
enediaminetetraacetic acid (MOPS SDS Running Buffer, Life Technologies #NP0001). Visualization of the target 
proteins in SDS-PAGE (Fig. 1b,c) indicated that targets bind to the beads by hydrophobic interaction. In Fig. 1b,c, 
the lanes labeled “No DNA” indicate that template DNA was omitted in these IVT-HMB reactions. IVT-HMB 
protein yields were estimated by comparison to bovine serum albumin (BSA) standards (Bio-Rad #500-0007) run 
on the same gel following visualization by silver stain (Pierce #24612). Molecular weight standards were Precision 
Plus Protein Dual Color Standards (Bio-Rad #161-0374).
Bullets for genetic immunization. The Helios gene gun (Bio-Rad #165-2451) uses a burst of helium gas 
to propel DNA-bound gold particles, which have been adhered on the inside of a piece of tubing, to the der-
mal tissues. Formation of DNA-gold micronanoplexes was based on Svarovsky et al.31 with slight modifications. 
Unless noted, molecular grade water and room temperature were used throughout this process. Bullets for the 
gene gun consisted of 1 cm length pieces of tubing that were coated on the inner surface with the DNA-gold 
micronanoplexes. Tefzel tubing (0.125 in. OD, 0.093 in. ID; Bio-Rad #165–2441) was washed with ethanol and 
then acetone by pulling the solutions through using a vacuum, followed by drying for 30 min by flowing inert 
gas through the tubing at a flowrate of 5 L/min. The washed tubing was stored in enclosed circles by connecting 
the ends with adapter tubing (silicone, 3/32 in. I.D., 5/32 in. O.D., Tygon 3350; Saint-Gobain #ABW00004). On 
the day of bullet preparation, the Tefzel tubing was cut into 33 cm lengths and attached to a non-Luer Lok 10 mL 
syringe, with plunger, via adapter tubing cut at a 1 cm length. The syringe barrel was retracted by approximately 
1 mL to facilitate later expulsion of liquid.
The micron-sized particles (microgold-PEI) and nanometer-sized particles (DNA-nanogold) are prepared 
separately and then mixed to allow association between the positively-charged polyethylenimine and the 
negatively-charged DNA (Fig. 2a).
Preparation of microgold-PEI. Micron-sized gold particles (microgold-PEI) (Fig. 2a) that were coated 
sequentially with 11-mercaptoundecanoic acid and polyethylenimine (PEI) were prepared as follows. Two 
grams of unmodified micron gold particles (Ferro, Inc. #J5G2000; or Bio-Rad #165–2264) were introduced to 
a glass flask. Within a fume hood, 15 mL of concentrated (98%) sulfuric acid was added. While mixing, 5 mL 
of 30% hydrogen peroxide was added dropwise to minimize exothermic heating. The solution was allowed to 
cool to room temperature for approximately 20 min. After decanting and discarding the supernatant, the gold 
was washed three times with 50 mL of water, transferred to a 50 mL polypropylene tube, and washed four times 
with 40 mL of water with mixing by vortex. The supernatant was decanted and discarded. The gold was washed 
twice with 20 mL of 100% ethanol. Centrifugation at 2000 rpm facilitated discarding of the supernatant. The 
gold was mixed with 20 mL of ethanol using a vortex, and 0.5 g of 11-mercaptoundecanoic acid (Sigma-Aldrich 
#450561; stored under desiccant) was added to allow alkanethiol modification of the gold surface. The solution 
was shaken horizontally at 1400 rpm for 2 h under protection from light and then centrifuged at 900 g for 2 min. 
After discarding the clear supernatant using a pipet, the gold was mixed by vortex in 20 mL of a 0.1 M solution 
of 2-(N-morpholino)ethanesulfonic acid (MES; brought to pH 6.0 with sodium hydroxide and 0.2 μ m-filtered). 
Mixing by vortex followed addition of 300 mg of N-hydroxysuccinimide (Sigma-Aldrich #130672; stored under 
nitrogen and desiccant) and addition of 200 mg of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydro-
chloride (Sigma-Aldrich #E1769; purchased within 6 months and stored under nitrogen and desiccant), which 
activated the carboxylic acid groups of 11-mercaptoundecanoic acid for later amide bond linkage66 to PEI. The 
solution was shaken horizontally at 1400 rpm for 30 min in the dark. During this incubation, 2 g of branched PEI 
(average MW ~25,000; Sigma-Aldrich #408727) was vigorously vortexed in 15 mL of water in a polypropylene 
tube, and the pH was adjusted to 9 with ~1 mL of HCl in order to protonate the amine groups, before adjusting 
the final volume to 20 mL using water. After centrifugation of the gold slurry for 2 min at 900 g, the supernatant 
was decanted and discarded. The PEI solution was added to the gold pellet, mixed by vortex, and then shaken 
horizontally at 1400 rpm for 2 h in the dark. After centrifugation for 2 min at 900g, the supernatant was discarded 
via pipet. The pellet was washed twice with 40 mL of water and the supernatant discarded via pipet. The gold 
was frozen at − 80 °C for 30 min prior to lyophilization overnight in the dark. The microgold-PEI was stored at 
4 °C in the dark and under nitrogen, and used within 3 months, due to gradual loss of binding capacity. Binding 
capacity of the microgold-PEI can be verified by comparison of the absorbance at 260 nm of the supernatants 
from 10 μ g of DNA incubated for 30 min in 0.1 mL of 0.1 M MES, pH 6.0, in the presence vs. the absence of 3 mg 
of microgold-PEI.
Preparation of nanogold. Nanometer-sized gold particles modified with cysteamine (nanogold) (Fig. 2a) 
were prepared as follows. Upon receipt, a 1 gram stock of hydrogen tetrachloroaurate(III) trihydrate (Alfa Aesar 
#36400-03; or Sigma-Aldrich #520918-1G) was suspended in 5 mL of water to yield 508 mM of HAuCl4. This 
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solution was stored at 4 °C under nitrogen gas and used within 6 months. Upon the day of bullet preparation, a 
1.59 mM solution of HAuCl4 was prepared by adding 62.5 μ L of 508 mM HAuCl4 to 20 mL of water. Under vig-
orous stirring and protection from light, 200 μ L of 213 mM cysteamine (CAS number 60-23-1; Sigma-Aldrich 
#30070; or Santa Cruz #sc-217991) was added dropwise, upon which the yellow solution turned darker. Due to 
rapid oxidation of cysteamine, the cysteamine solution was freshly prepared from a recently-ordered, unopened 
bottle that had been maintained under nitrogen gas and desiccant. After 10 min of continuous stirring of the 
HAuCl4/cysteamine solution, 5 μ L of a 10 mM solution of the reducing agent sodium borohydride (Sigma-Aldrich 
#480886; stored under desiccant) was rapidly injected directly into the stirring solution. The sodium borohydride 
solution had been prepared immediately before use and discarded immediately after use due to release of hydro-
gen gas upon its dissolution in water. Mixing of the nanogold suspension (1.59 mM HAuCl4, 2.13 mM cysteamine, 
2.5 μ M NaBH4) was continued for 30 min, upon which the color of the clear solution turned a deep wine red, 
indicating formation of gold particles of ~36 nm size31,33. The nanogold suspension was stored at 4 °C in the dark 
and under nitrogen, and used within 48 h.
Preparation of DNA-nanogold. Cysteamine-modified nanogold was complexed with DNA to form 
DNA-nanogold (Fig. 2a) as follows. Plasmid DNA and CpG oligodeoxynucleotide solutions were combined in a 
polypropylene tube. Nanogold suspension (1.59 mM HAuCl4, 2.13 mM cysteamine, 2.5 μ M NaBH4) was added 
such that, per bullet, 57 μ L of nanogold suspension was mixed with ≤ 10 μ g total of plasmid DNA plus CpG that 
was in a volume of ≤ 15 μ L. If necessary to reduce the volume, plasmid DNA had been precipitated with ethanol 
and sodium acetate prior to suspension in water. The DNA-nanogold suspension was incubated at room tem-
perature for 5 min, upon which the suspension turned from red to violet, indicating formation of complexes of 
300–400 nm size31.
Preparation of DNA-gold micronanoplexes and bullets. DNA-gold micronanoplexes were formed 
by combining microgold-PEI and DNA-nanogold (Fig. 2a) as follows. A 167 mg/mL slurry of microgold-PEI 
was prepared by combining, per bullet, 1 mg of lyophilized microgold-PEI with 6 μ L of 0.1 M MES, pH 6.0. 
DNA-gold micronanoplexes were formed upon combining equivalent bullet-volumes of the microgold-PEI and 
DNA-nanogold solutions. The micronanoplexes mixture was incubated at room temperature with occasional 
mixing by vortex for 10 min, during which time the supernatant became less colored. This supernatant can be 
analyzed by ethidium-bromide-stained agarose gel electrophoresis in order to estimate DNA complexation into 
micronanoplexes. The gold was ethanol-washed three times by centrifugation at 100g for 1 min, removing and 
discarding the supernatant via aspiration, and vortexing upon addition of ethanol (0.1 mL per 1 bullet). These 
washes were also facilitated by gentle, repeated pipetting. The final supernatant was removed by aspiration and 
discarded.
Bullets were prepared in a fume hood. The ethanol-washed DNA-gold micronanoplexes were suspended in 
55 μ L (per bullet) of 1-butanol (Sigma-Aldrich #360465) via tube inversion and gentle pipetting. Immediately 
upon vortexing, the suspension was rapidly drawn into the horizontally-laid 33 cm-length Tefzel tubing via 
syringe aspiration, up to a maximum distance of approximately 24 cm into the tubing. The tubing was allowed 
to rest for 5–10 min to allow the gold to settle on the inner surface of the tubing. The butanol, now colorless, was 
gently expelled from the open end of the tubing using the attached syringe. The gold in the tubing was dried for 
10–20 min by flowing helium through the tubing at a rate of 5 L/min, upon which the gold turned a lighter shade. 
Over-drying can inhibit release of the DNA-gold micronanoplexes upon firing. Release of the gold can be visual-
ized by firing bullets against a piece of paper. The tubing was enclosed by circularization via adapter tubing until 
the time that the tubing could be cut into 0.5-inch lengths (Bio-Rad Tubing Cutter #165–2422), yielding approx-
imately 19 bullets for each 24 cm length of gold-bound tubing. Bullets were stored in tubes containing desiccant 
(Drierite #21001) and used within 3 days.
Genetic immunization of mice. All procedures were performed in accordance with protocols approved 
by the Institutional Animal Care and Use Committee at Arizona State University. Six- to eight-week-old female 
A/J and BALB/c mice were purchased from The Jackson Laboratory and maintained in-house for at least 1 week 
before use. A/J mice (5 mice/target) were chosen based on previous experimental data showing strong antibody 
production upon biolistic immunization with micron-gold42, and BALB/c mice were used for immunization of 
ASFV targets in pCMVi-LSrCOMPTT. Mice were housed on a 12 h dark/light schedule in Thoren Maxi-Miser 
cages containing Irradiated Teklad Sani Chips (Harlan #7990) and Ancare Nestlets. Cages were maintained on 
ventilated racks and under pathogen-free conditions. Mice were provided food (Teklad Global 18% Protein 
Rodent Diet; Harlan #2918) and water ad libitum.
Groups of five mice were genetically immunized in the ear skin pinnae using the gene gun and a helium 
pressure of 350 psi. The presence of less than five mice in the results (Supplementary Figs 1–3) indicates loss of 
the mouse. Each genetic immunization prime or boost consisted of two bullets, with one bullet delivered to the 
pinnae of each ear. A double-prime consisted of two shots per mouse on day 1, followed by two shots per mouse 
on day 2 or 3. The shots on these days were done on alternate sides of the ear pinnae. Naïve mice were untreated.
Immunization for the 17 pCMVi-LSrCOMPTT constructs were as follows. DNA amounts are per bullet. All 
targets were immunized with 1 μ g of pCMVi-LSrCOMPTT construct and 1 μ g of class C CpG as a double-prime 
on days one and three, plus two boosts at two week intervals. Third and fourth boosts were done at ≥ 2 weeks 
for some targets, depending on the titer, and contained 1 μ g of pCMVi-LSrCOMPTT construct, 21 ng of 
pCMVi-LS-LTA-R192G, 104 ng of pCMVi-LTB, and 1 μ g of Class B CpG. A third genetic boost was done for 
BamA, TolC, FupB, CapA, CapB, FTT1406, p54, CD2v, and C-type lectin. A fourth boost was done for CapA, 
FTT1406, p54, CD2v, and C-type lectin. Sera analyses from this set are in Supplementary Fig. 1a–q.
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A separate immunization of five targets (PilQ, OMEP, BamA, Flpp3 and FTT1406) in pCMVi-LSrCOMPTT 
suggested improved responses using altered adjuvants and also allowed analysis of protein boosts using 
antigen from IVT-HMB reactions (Supplementary Fig. 2a–k). The targets were immunized with 1 μ g of 
pCMVi-LSrCOMPTT construct, 21 ng of pCMVi-LS-LTA-R192G, 104 ng of pCMVi-LTB, and 5 μ g of Class B 
CpG as a double-prime on days one and two. The first boost was done after two weeks with the same DNA 
except that the CpG was dropped to 1 μ g, since release of DNA-gold was inhibited upon firing with 5 μ g of CpG 
per bullet. A second boost with the same DNA as the first boost was done after 5 weeks for OMEP, BamA and 
FTT1406. Serum analyses for this set are in Supplementary Fig. 2a–k. Comparison with the first immunization set 
containing all 17 pCMVi-LSrCOMPTT constructs indicated generally higher responses were obtained using the 
adjuvants in this second immunization set, as follows. Higher ELISA titers were achieved with fewer DNA boosts 
for PilQ (Supplementary Fig. 2a, one boost vs. Supplementary Fig. 1a, two boosts) and BamA (Supplementary 
Fig. 2d, one boost vs. Supplementary Fig. 1c, three boosts), and with the same number of boosts (two) for OMEP 
(Supplementary Fig. 2c vs. Supplementary Fig. 1b). Similar titers were obtained for Flpp3 using fewer boosts 
(Supplementary Fig. 2g, one boost vs. Supplementary Fig. 1i, two boosts).
Immunization for the nine pCMVi-UB constructs (FupA, FupB, FTT0759, CapA, CapB, CapC, p54, CD2v, 
and C-type lectin) were as follows. The targets were immunized with 1 μ g of pCMVi-UB construct, 21 ng of 
pCMVi-LS-LTA-R192G, 104 ng of pCMVi-LTB, and 2.5 μ g of Class B CpG as a double-prime on days one 
and three. For CD2v, the 1 μ g of target-specific DNA was equally split between pCMVi-UB and pCMVi-LS 
constructs. For all targets, a genetic boost after 2 weeks contained 1 μ g of pCMVi-UB construct, 21 ng 
pCMVi-LS-LTA-R192G, 104 ng pCMVi-LTB, and 1 μ g class B CpG. For this boost, pCMVi-LSrCOMPTT con-
structs were used instead of pCMVi-UB for CapA, CapB, and FupA upon comparison with the previous immu-
nization set of ELISA titers following the double primes. Sera analyses for this set are in Supplementary Fig. 3a,b.
IVT-HMB protein for boosts. Membrane protein derived from IVT-HMB reactions was used in pro-
tein boosts for BamA immunizations in pCMVi-LSrCOMPTT (Supplementary Fig. 2f ), for FTT1406 in 
pCMVi-LSrCOMPTT (Supplementary Fig. 2j,k), and for the nine targets in pCMVi-UB (immunoblot results for 
p54 are in Supplementary Fig. 3c). IVT-HMB protein used in immunizations was derived from pET-32b-TEV 
constructs (Supplementary Fig. 4), except FTT0759 antigen was from two LEEs encompassing amino acids 
59–128 and 120–220 (Fig. 1c), and CD2v antigen was from two LEEs encompassing amino acids 10–202 and 
170–355 (Fig. 1c). Mice were injected intraperitoneally with 0.1 mL volume of a 50% (vol/vol) solution of the 
adjuvant alum (Life Technologies #77161) containing 1 μ g of class C CpG plus 1 μ g of target protein bound to 
magnetic beads. The protein-bound beads had been washed four times in PBS with a final suspension in PBS. 
Prior to injection, the boost solution was mixed at 600 rpm at room temperature for 30 min. Protein immuniza-
tions in pCMVi-UB constructs included two boosts with IVT-HMB protein. Positive immunoblot results for p54 
in pCMVi-UB are in Supplementary Fig. 3c. Immunoblots for the other eight targets yielded no measurable target 
recognition at the lowest serum dilutions tested (1:400-1:1000), and further indicated that, as with p54, injection 
of IVT-HMB protein contributed to recognition of several irrelevant proteins (serum dilutions of 1:10,000 and 
1:100,000).
Serum preparation. Sera samples were obtained by submandibular bleeding67. Final bleeds were done by 
cardiac puncture under anesthesia by tribromoethanol. Sera were prepared using 400–600 μ L or 3.5 mL venous 
blood collection tubes with clot activator and gel for serum separation (Becton, Dickinson #365956 or #367981, 
respectively). Serum was brought to a final concentration of 50% glycerol by adding sterile 80% glycerol. These 
sera were stored at − 20 °C until use. Serum dilutions were based on the 50% glycerol preparations.
ELISAs. To ensure that positive immune responses were relevant to only the target membrane protein, protein 
antigens used to characterize mouse sera lacked protein sequence tags that were also present in the immuniza-
tion steps. For enzyme-linked immunosorbent assays (ELISA), 100 ng of protein from IVT-HMB was coated 
in wells overnight at 4 °C using 100 μ L per well in 0.03 M NaHCO3, 0.02 M Na2CO3, and 96-well flat-bottom 
MaxiSorp plates (Nunc #439454). Wells were washed three times in TBST (20 mM Tris, 136 mM NaCl, pH 7.4, 
0.05% Tween-20) on a BioTek ELx405 platewasher. Manual washing using a magnet was necessary when yields 
of IVT-HMB protein were less than 5 ng of target protein per μ L of IVT-HMB reaction. Blocking was done at 
37 °C for 1 h in 200 μ L/well of TBST containing 3% BSA (heat shock fraction, pH 7, ≥ 98%; Sigma #A7906-500 G) 
followed by washing as above. Wells were incubated at 37 °C for 1 h in 100 μ L/well of serum diluted in TBST 
containing 3% BSA, followed by washing performed as described above. Wells were incubated at 37 °C for 1 h in 
100 μ L/well of secondary antibody (goat anti-mouse IgG [H+ L], HRP conjugate; Life Technologies #626520) at 
a 1:3000 dilution in TBST containing 3% BSA, followed by washing as above. Detection was done by addition of 
100 μ L per well of ABTS (2,2′ -azino-di[3-ethyl-benzthiazoline-6-sulfonate]) Peroxidase Substrate, 1-Component 
(KPL #50-66-06), incubation at 37 °C for 30 min, addition of 100 μ L per well of 0.5 M HCl, and measurement at 
415 nm in a Molecular Devices SpectraMax 190 plate reader.
Western blots. Immunoblot analyses of polyclonal antibody containing sera used SDS-PAGE gels as 
described above. Transfer to pre-wet nitrocellulose (Pall #66485) was performed at 10 V and 4 °C overnight in 
chilled Tris-glycine (25 mM Tris, 192 mM glycine, pH 8.3) containing 20% methanol and using a Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad #170-3930). Blocking and antibody steps were done on an orbital 
shaker at 0.5 revolution/s. Blocking was in TBST containing 5% BSA for 1 h at 37 °C or 2 h at room temperature. 
Subsequent steps were performed at room temperature. The membrane was incubated with primary antibody 
diluted in TBST containing 1% BSA for 1 h, then washed by rinsing twice in TBST and incubating twice for 5 min 
in TBST. The membrane was incubated with secondary antibody (goat anti-mouse IgG [H+ L], HRP conjugate) 
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at a 1:2000 dilution in TBST containing 1% BSA for 1 h, and then washed as above. Detection was with the 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific #34080) and using a Bio-Rad ChemiDoc 
XRS System. Molecular weight markers for immunoblots were the MagicMark XP Western Protein Standard (Life 
Technologies #LC5603).
Protein expression and detergent-solubilization. Plasmid constructs encoding the four tagless forms 
of F. tularensis membrane proteins in Fig. 3a were expressed using fresh transformants of E. coli C43(DE3) as 
follows. Cultures were grown at 37 °C with shaking at 250 rpm in 14 mL snap-cap tubes (Corning #352057) con-
taining LB medium (10 g peptone, 5 g yeast extract, 5 g NaCl) and 50 μ g/mL carbenicillin. Pre-warmed medium 
(5 mL) was inoculated with 300 μ L of overnight culture. When the culture absorbance at 600 nm reached 0.5–0.8, 
expression was induced with 0.5 mM of isopropyl β -D-1-thiogalactopyranoside. After 3 h, cell pellets were har-
vested from each 50 μ L (for total protein) and 3 mL (for detergent-solubilization) of culture and stored at − 20 °C.
Detergent-solubilized fractions of the four tagless F. tularensis membrane proteins were prepared from total 
cell protein obtained from 3 mL of culture as follows. All steps were done at room temperature unless noted. Cell 
pellets were thawed for 5 min prior to suspension in 250 μ L of 50 mM sodium phosphate, pH 7.3, 300 mM NaCl, 
10 mM imidazole, 1% DDM (> 99.5%, for crystallography; Glycon #D97002-C), 2 mg/mL of chicken egg white 
lysozyme (Sigma #L6876), 0.01 mg/mL deoxyribonuclease I from bovine pancreas (EMD Millipore #260913), 
and 20 mM MgCl2, plus 1 tablet of Complete Mini, EDTA-free Protease Inhibitor per 10 mL of solution. The 
cell suspension was pipetted up & down ten times using a 1000 μ L tip and then incubated for 15 min, in which 
every 5 min the samples were mixed by vortex for 5 s. To ensure lysis, three freeze-thaw cycles were done by 
incubating the sample at − 80 °C for at least 10 min, thawing completely, and mixing by vortex. Samples were sub-
jected to three cycles of 2 min of room-temperature bath sonication (Health-Sonics Corporation 0.8 Amp model 
#T1–9 C) plus 1 min on ice. Samples were centrifuged at 17,000 g for 15 min at 4 °C. The supernatant containing 
DDM-solubilized proteins was removed and stored at − 20 °C. For Fig. 3a, 10 μ L of the DDM-solubilized sample 
was combined with 5 μ L of 4X SDS-PAGE Loading Solution, of which 2 μ L was run on SDS-PAGE. For the total 
protein samples in Fig. 3a, the cell pellet from 50 μ L of culture was suspended in 25 μ L of 1X SDS-PAGE Loading 
Solution, of which 10 μ L was loaded. Protein concentration of BL21(DE3) (Fig. 3a) was determined by Bradford 
assay (Bio-Rad #500-0002).
Membrane-targeting of F. tularensis BamA (Fig. 3b) was analyzed by detergent-solubilization of a mem-
brane fraction as follows. F. tularensis BamA containing the signal sequence from E. coli BamA (EcBamA1–20 
-FTT157323–792) was expressed in BL21(DE3) using construct pCDF-BAD-EcBam-FTT1573. Growth was at 37 °C 
in 1 liter of LB medium containing 50 μ g/mL spectinomycin. When the absorbance at 600 nm reached 0.6, expres-
sion was induced with 0.2% arabinose. Cells were harvested after 3 h and frozen in liquid nitrogen prior to storage 
at − 80 °C. The cell pellet (2.5 g, wet weight) was thawed, suspended in 10 mL of chilled Buffer A (50 mM HEPES, 
pH 7.3, 300 mM NaCl, and 1 Protease Inhibitor Cocktail Tablet, EDTA-Free [Sigma #S8830]), and sonicated for 
three 30 s cycles at 50% duty cycle and 50% power using an ultrasonic homogenizer Model 300 V/T (Biologics, 
Inc.). Additional Buffer A was added to bring the total volume to 26 mL prior to centrifugation at 100,000g for 
40 min at 4 °C. The supernatant was removed. The pelleted membrane fraction (0.6 g) was suspended in 2.4 mL 
of Buffer A and homogenized using a Teflon-in-glass homogenizer (Corning #7724 T-5) at 4 °C. To 1.8 mL of the 
membrane suspension was added 225 μ L of 10% (wt/vol) LDAO and 225 μ L of glycerol. To 0.9 mL of the mem-
brane suspension was added 100 μ L of 10% (wt/vol) DDM. The membrane-detergent suspensions were gently 
shaken for 1 h at 4 °C prior to centrifugation at 16,800g for 40 min at 4 °C. Supernatant and pellet samples were 
frozen in liquid nitrogen and stored at − 80 °C until the Western was performed as described above and using a 
1:3000 dilution of secondary antibody.
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